# Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

Study · id `cardio:ct-nct01932970` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01932970](<https://clinicaltrials.gov/study/NCT01932970>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01932970

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

## Technical summary

Registry record NCT01932970. Allocation not applicable; no masking; primary purpose treatment. Start 2013-08-12 (actual); primary completion 2014-01-14 (actual). Results posted on 2017-04-04.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 158 participants (enrolled count; ClinicalTrials.gov record NCT01932970, source copy `cardio:ctgov-nct01932970-2018-10-17`, retrieved 2026-10-26)
- Started: 2013-08-12 (actual) (ClinicalTrials.gov record NCT01932970, source copy `cardio:ctgov-nct01932970-2018-10-17`, retrieved 2026-10-26)
- Primary completion: 2014-01-14 (actual) (ClinicalTrials.gov record NCT01932970, source copy `cardio:ctgov-nct01932970-2018-10-17`, retrieved 2026-10-26)
- Completion: 2017-02-14 (actual) (ClinicalTrials.gov record NCT01932970, source copy `cardio:ctgov-nct01932970-2018-10-17`, retrieved 2026-10-26)
- Results first posted: 2017-04-04 (ClinicalTrials.gov record NCT01932970, source copy `cardio:ctgov-nct01932970-2018-10-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01932970, source copy `cardio:ctgov-nct01932970-2018-10-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01932970-2018-10-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
- Condition: Hyperparathyroidism, Secondary
- Intervention (Drug): Etelcalcetide
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 2131138f2d9915d671c93a11fcffac6ef0c43522e2c21e8ebdf9395a18b4f2df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
